FDA Arthritis Drug Advisory Committee
Ciba-Geigy's Voltaren NDA is on the agenda for the panel's May 16-17 meeting. The panel will also review the status of revised guidelines for the clinical evaluation of NSAIDs. McNeil Labs will also report on a follow-up program on the long-term effects of Suprol. Merck's Clinoril is also on the agenda. The committee will meet in FDA's Parklawn conference rooms D & E 8:30 a.m. both days.
You may also be interested in...
Illumina announced on 21 September it will buy back Grail, which is planning to commercialize its multi-cancer early detection blood test Galleri in 2021. See what Illumina’s CEO Francis deSouza said about it here.
Yes, Gottlieb’s in there twice; things get complicated when an agency starts to lose credibility.
Newly published data and results presented at ESMO for Amgen’s sotorasib (AMG 510) show relatively long-lasting responses and progression-free survival in lung cancer.